NCT03021018CompletedPhase 2
A Multicenter, Open-Label, Randomized, Parallel-Group, Active-Controlled Study to Assess the Efficacy and Safety of Brivaracetam Administered Intravenously as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
UCB Biopharma S.P.R.L.14 sites in 1 country46 target enrollmentStarted: February 6, 2017Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 46
- Locations
- 14
- Primary Endpoint
- Time to Next Seizure (Per Clinical Observation With Electroencephalogram [EEG] Confirmation) or Rescue Medication
Study Overview
Brief Summary
The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject is male or female, 18 to 70 years of age, inclusive
- •Subject has an established diagnosis of epilepsy
- •Subject has been admitted to the institution's Epilepsy Monitoring Unit (EMU) for seizure characterization or noninvasive presurgical evaluation or such admission is planned within 21 days of Screening
Exclusion Criteria
- •Subject has previously participated in this study and was treated with study drug. Re-screen is permitted
- •Subject has participated in another study of an investigational medicinal product (IMP) or a medical device within the previous 30 days of Epilepsy Monitoring Unit (EMU) admission or is currently participating in another study of an IMP or a medical device
- •Subject has taken brivaracetam (BRV) in the 21 days prior to EMU admission
- •History or presence of status epilepticus during the 6 months prior to EMU admission
- •Subject has a medical or psychiatric condition that in the opinion of the Investigator could jeopardize or would compromise the subject's ability to participate in this study
- •Subject has > 2x upper limit of normal (ULN) of any of the following: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or > ULN total bilirubin
- •Subject has chronic liver disease
- •Subject has hypersensitivity to BRV or any of its excipients
- •Subject has a history of alcohol or drug abuse during the 6 months prior to EMU admission
- •Subject with a history of psychogenic seizures
- •Subject is a pregnant or lactating female
- •Subject has a history of a significant Adverse Event (AE) due to a benzodiazepine in the opinion of the Investigator
- •Subject has respiratory failure (or is at risk for respiratory failure), untreated sleep apnea, or other severe cardiorespiratory disease with New York Heart Association Class III or IV functional status, or requires supplemental oxygen
- •Subject has acute narrow-angle glaucoma or myasthenia gravis
- •Subject is receiving benzodiazepine treatment (defined as an average of >=4 administrations per week) that started less than 28 days prior to EMU admission
- •Subject has a known allergic reaction or intolerance to benzodiazepines or benzodiazepine excipients
Arms & Interventions
Brivaracetam (BRV) 100 mg
Experimental
Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period
Intervention: Brivaracetam (Drug)
Brivaracetam (BRV) 200 mg
Experimental
Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period
Intervention: Brivaracetam (Drug)
Lorazepam (LZP)
Active Comparator
Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.
Intervention: Lorazepam (Drug)
Outcomes
Primary Outcomes
Time to Next Seizure (Per Clinical Observation With Electroencephalogram [EEG] Confirmation) or Rescue Medication
Time Frame: During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2)
This variable was calculated in hours. The event of next seizure was defined as the first seizure (clinically observed with electroencephalogram \[EEG\] confirmation) with the start date and time within 12 hours after the end of investigational medicinal product (IMP) administration.
Secondary Outcomes
- Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 6 Hours After the End of Study Drug Administration(At 6 hours after the end of study drug administration)
- Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 12 Hours After the End of Study Drug Administration(At 12 hours after the end of study drug administration)
- Percentage of Subjects Who Receive Rescue Medication During the 8 Hours After the End of Study Drug Administration(During the 8 hours after the end of study drug administration)
- Time to Next Seizure (Per Clinical Observation) or Rescue Medication(During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2))
- Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 8 Hours After the End of Study Drug Administration(At 8 hours after the end of study drug administration)
- Percentage of Subjects Who Receive Rescue Medication During the 6 Hours After the End of Study Drug Administration(During the 6 hours after the end of study drug administration)
- Percentage of Subjects Who Receive Rescue Medication During the 12 Hours After the End of Study Drug Administration(During the 12 hours after the end of study drug administration)
Investigators
Study Sites (14)
Loading locations...
Similar Trials
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With EpilepsyPartial Seizures With or Without Secondary GeneralizationEpilepsyNCT03083665UCB Biopharma SRL449
Completed
Phase 3
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset SeizuresEpilepsyNCT00490035UCB Pharma SA399
Completed
Phase 2
Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy EndpointPhotosensitive EpilepsyNCT03580707Rosenfeld, William E., M.D.16
Active, not recruiting
Phase 3
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence EpilepsyChildhood Absence EpilepsyNCT06315322UCB Biopharma SRL70
Completed
Phase 3
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary GeneralizationPartial Seizures With or Without Secondary GeneralizationEpilepsyNCT03685630UCB Biopharma S.P.R.L.10